Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.
Julia Wulfkuhle(University of California, San Francisco), Denise M. Wolf, Laura van ‘t Veer, Lajos Pusztai(Yale University), Lamorna Brown Swigart(University of California, San Francisco), Minetta C. Liu(Mayo Clinic), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Laura J. Esserman(University of California, San Francisco), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Michael J. Campbell(University of California, San Francisco), Rita Nanda(University of Chicago), Emanuel Petricoin(George Mason University)
Cited by 11
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k